INTRODUCTION

Hydrophobic lipids are insoluble in blood plasma and they are transported to the tissues as lipoproteins with cholesterol esters and triglycerides in the core and phospholipids, free cholesterol, and apolipoproteins on the surface. Elevated plasma levels of high-density lipoprotein (HDL-C) and apolipoprotein A1 (ApoAl) have been shown to be associated with a reduced risk of cardiovascular disease (CVD). In addition to the potential cardioprotective function, HDL and ApoA1, which is the major apoliproprotein of HDL, are also characterized by antidiabetic properties. Increased plasma HDL and ApoA1 improves glycemic control in patients with type 2 diabetes mellitus (DM2) by enhancing function of pancreatic β-cells and increasing insulin sensitivity (Rye, 2016). ApoAl also stimulates the glucose uptake in vivo in skeletal and cardiac muscles (Fritzen, 2020).

The hydrophobic core of low-density lipoproteins (LDL) consists of approximately 170 triglycerides, 1500 cholesterol esters, a hydrophilic shell consisting of 700 molecules of phospholipids, approximately 500 molecules of unesterified cholesterol, and one large ApoB with molecular weight of 500 kDa. ApoB is the major apolipoprotein and is a carrier for the following lipids: chylomicrons, LDL, very low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), and lipoproteins (a). ApoB is not found in high-density lipoproteins (HDL), the latter being reduced to lipoproteins with ApoA. Hepatic ApoB has a molecular weight of 540 000 Da. There are two circulating forms of ApoB – ApoB48 (from the small intestine) and ApoB100 (from the liver) (Devaraj, 2021).

Under oxidative stress, LDL oxidation occurs in the process of lipid peroxidation, mainly with the participation of phospholipid molecules. Under pathological conditions, plasma lipoproteins containing ApoB penetrate through the damaged endothelium into the subendothelial intima of blood vessels and oxidized by ROS (reactive oxygen species). Thus, LDL is modified to oxLDL (Khatana, 2020).

Elevated plasma levels of low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and, especially, oxLDL have been shown to be associated with an increased risk of CVD. The ApoB/ApoA1 ratio is associated with DM2 and is proposed as a promising biomarker for CVD prediction (Mao, 2017). A meta-analysis also showed that elevated ApoB levels and decreased ApoAl levels, as well as the ApoB/Al ratio, are risk factors of a first ischemic stroke (Dong, 2015).

Since COVID-19 infection is associated with dyslipidemia and cardiovascular complications (Zamanian, 2020; Begue, 2021; Feingold, 2021; Kocar, 2021), the aim of the study was to determine the content of ApoA1, ApoB, and oxLDL in the plasma of patients with COVID-19, diabetes, and CVD.

MATERIALS AND METHODS

The study was conducted in the Diabetology Department of the Institute. The research protocol was approved by the Ethics Committee of the Institute. All patients signed an informed consent for further diagnostic and scientific research.

Blood was obtained by standard venipuncture and stored in EDTA tubes. Plasma was separated by centrifugation for 10 min after blood collection. The samples were stored at –80°C until use. The amount of ApoA1, ApoB, and oxLDL was determined (n = 81) using an enzyme-linked immunosorbent assay (ELISA) kit (Elabscience, United States). Measurements were performed at an optical wavelength of 450 nm using an enzyme-linked immunosorbent assay analyzer Stat Fax 3200 (Awareness Technology, United States).

Glycated hemoglobin was determined using one HbA1c FS kit (DiaSys Diagnostic Systems GmbH, Germany). The measurements were performed at an optical wavelength of 660 nm.

Statistical analysis and data presentation were performed using the Origin 7.0 software. The results of the study are presented as M ± m. Student’s t-test was used for the comparison of data groups. Values of P ≤ 0.05 were considered significant.

RESULTS AND DISCUSSION

Blood plasma from 60 patients with diabetes (25 men, 35 women) and 21 patients with diabetes, CVD and COVID-19 (10 men, 11 women) was used. The blood from healthy people (n = 7) without comorbidities, representative of age, was used as the control. Four patients had a history of CVD. The level of Hb1Ac in patients with diabetes was 9.62 ± 0.27 and BMI was 30.69 ± 1.06 kg/m2. The fasting blood glucose concentration of patients with COVID-19 and diabetes mellitus was 9.6 ± 0.92 mM/L; at the time of discharge K 6.72 ± 0.62 mM/L. The average O2 saturation was 87.3 ± 0.7%, indicating a severe course of the disease.

As can be seen in Fig. 1, the average level of ApoA1 in the blood from healthy people was in the upper range of the normal level (1.88 g/L). In patients with diabetes, this value was much lower, 1.21 g/L, which is closer to the lower limit of normal. In patients with diabetes mellitus and COVID-19, the content of ApoA1 in the blood was approximately 0.25 g/L, which was more than four times less than the lower limit of normal content. Interestingly, differences between patients with COVID-19 and diabetes, COVID-19 and CVD, and patients with COVID-19 without comorbidities were not revealed (Fig. 1). In the blood from some patients with COVID-19, the level of ApoA1 decreased to almost zero: 0.09 g/L.

Fig. 1.
figure 1

Plasma ApoAl level in patients with diabetes and COVID-19 (g/L). 1—Control (n = 7); 2—patients with DM (n = 60); 3—patients with DM and COVID-19 (n = 16); 4—patients with COVID-19 (n = 5); 5—patients with COVID-19 and CVD (n = 4); M ± m. * Differences from control are significant, P \( \ll \) 0.0001; + differences from group two are significant, P \( \ll \) 0.0001.

The fact that the level of ApoA1 in the blood was not reduced in patients with COVID-19 and diabetes and CVD compared with patients without comorbidities, suggests that COVID-19 forms a set of much more powerful factors affecting the content of ApoA1, and such a decrease reaches the lower limit.

Decreased levels of ApoA1 in the blood from patients with diabetes and who have an increased risk of CVD have been reported in many studies (Cochran, 2021; Gao, 2021; Retnakaran, 2019; Sokolova, 2014). COVID-19 significantly affected lipid profiles with a decrease in total cholesterol (TC), HDL-C and LDL-C levels, and elevated triglycerides compared to controls. Plasma ApoA1 level in patients decreased by 55% compared to healthy people (Begue, 2021). Hypolipidemia was observed in patients with COVID-19 and it was positively correlated with disease severity (Wei, 2020). ApoA1 is characterized by anti-inflammatory properties, is involved in the regulation of the immune response, and a decrease in the amount of this lipoprotein affects the severity of COVID-19. Moreover, dysregulation of ApoA1 may contribute to possible side effects of COVID-19 on the nervous system (Yang, 2020; Zamanian, 2020).

The reason for the decreased amount of plasma ApoA1 may be the inhibition of its synthesis in the liver and/or replacement by amyloid A in blood HDL (Begue, 2021). In addition, chymase produced by mast cells may play an important role in the degradation of ApoA1 (Inoue, 2020).

The average level of ApoB in the blood from healthy people was 1.05 g/L, the value was within the normal range (normal range: 0.55–1.3 g/L for men and 0.6–1.4 g/L for women) (Fig. 2). In patients with diabetes, this value was higher, 1.15 g/L, which was closer to the upper limit of normal range. In patients with COVID-19, the content of ApoB in the blood was much higher than the control and normal range values (Fig. 2, bars 3–6). The difference between patients with COVID-19 without comorbidities and COVID-19 with diabetes and, especially, CVD should be noted (Fig. 1, bar 5 vs. bars 4 and 6).

Fig. 2.
figure 2

Plasma ApoB level in patients with diabetes, CVD, and COVID-19. 1—Control (n = 7); 2—patients with type 2 diabetes mellitus (n = 60); 3—mean data for all patients with COVID-19 (n = 21); 4—patients with COVID-19 and diabetes (n = 16); 5—patients with COVID-19 without comorbidities (n = 5); 6—patients with COVID-19 and CVD (n = 4); M ± m. Significant differences between the control and other groups were revealed (P < 0.05 for group two and P \( \ll \) 0.0001 for groups three to six); * differences from groups four and six were significant, P < 0.05.

A similar pattern was observed for oxLDL (Fig. 3). In patients with diabetes, the amount of oxLDL was above the control level. In patients with COVID-19, the content of oxLDL in the blood was much higher than the control level and the level in patients with diabetes (Fig. 3, bars 3–6). There was also a significant difference between patients with COVID-19 without comorbidities and COVID-19 with diabetes and CVD (Fig. 2, bar 5 vs. bars 4 and 6). Thus, the amount of ApoB and LDL derivatives, oxLDL, changed in the blood of patients with diabetes and patients with COVID-19 almost synchronously.

Fig. 3.
figure 3

Plasma oxLDL level in patients with diabetes, CVD, and COVID-19. 1—Control (n = 7); 2—patients with type 2 diabetes mellitus (n = 60); 3—average data for all patients with COVID-19 (n = 21); 4—patients with COVID-19 and diabetes (n = 16); 5—patients with COVID-19 without comorbidities (n = 5); 6—patients with COVID-19 and CVD (n = 4). M ± m. Differences between the control and other groups were significant (P < 0.05 for group two and P \( \ll \) 0.0001 for groups three to six); * differences from groups four and six were significant, P < 0.05.

It has been proven that high LDL content causes the accumulation of cholesterol on the walls of blood vessels, significantly increasing the risk of atherosclerosis (AS) and CVD (Sniderman, 2019; Sokolova, 2017; Yan, 2020). Since ApoB is the major protein of LDL, the major transporter of cholesterol to cells, its concentration indicates the degree of risk of coronary heart disease. The concentration of ApoB in the blood is now considered a more reliable indicator of the risk of developing AS than total cholesterol (TC) or LDL-cholesterol (LDL-C). Together with determining the concentration of ApoB, the content of apolipoprotein A1 (ApoA1) should be determined. If the ratio of the concentration of ApoB to ApoA1 is high, then the risk of coronary heart disease is very high. It was proposed to set the normal range for ApoB to above 1.2 g/L. For risk groups, it was recommended to maintain an ApoB content at a level lower than 0.9 g/L regardless of gender. The range limit values of the ApoB/ApoAl ratio can be used for the determination of the risk level for men < 0.9 and for women < 0.8 (Sniderman, 2019; Sokolova, 2014):

Groups

ApoB/ApoA1

Control

0.558

DM

0.952

Covid-19 + DM

9.041

Covid-19 + CVD

9.993

In the control group, this indicator was within the normal range, it was slightly higher than the normal range values in patients with diabetes, and it increased in patients with COVID-19 infection by an order of magnitude compared with patients with diabetes, indicating an extremely high risk of cardiovascular complications.

AS is characterized as a chronic inflammatory reaction to cholesterol deposition in the arteries. LDL, especially its oxidized form, oxLDL, play a crucial role in the onset and development of AS, inducing endothelial cell dysfunction, involving monocytes/macrophages, and contributing to chronic inflammation. Macrophages absorb oxLDL, forming foam cells that ultimately release proinflammatory cytokines and exacerbate local inflammation (Kocar, 2021; Yan, 2020).

We have shown that both ApoB and oxLDL levels increase with a high probability (P = 5.85 × 10–8 and 2.46 × 10–11, respectively), indicating an increased risk of CVD.

SARS-related dyslipidemia has been confirmed. However, some authors found that serum TC, HDL, and LDL cholesterol levels were significantly lower in patients with COVID-19 compared to healthy people (Kocar, 2021; Wei, 2020). It has been concluded that patients with COVID-19 develop hypolipidemia when symptoms are mild and hypolipidemia worsen with the severity of the disease (Wei, 2020). However, the authors use the term “hypolipidemia” to refer to patients with total cholesterol <174 mg/dL. This definition of hypolipidemia is incorrect in the absence of a genetic diagnosis (Fogacci, 2020). The prevalence of patients with high cardiovascular risk may explain the observed LDL results. The low level of LDL cholesterol in this group was probably due to a more intense decrease in lipid levels as a result of therapy. In addition, we investigated the content of ApoB and not LDL-C, and they can have different dynamics. In blood samples obtained from patients with COVID-19, only the level of ApoA1was significantly reduced.

CONCLUSIONS

The level of plasma ApoA1 in patients with diabetes and, especially, COVID-19 was significantly lower than that in the blood of healthy people. The level of ApoB and oxLDL in the blood from patients with diabetes and, especially, COVID-19 was significantly higher than in the blood of healthy people. Differences between patients with COVID-19 without comorbidities and COVID-19 with diabetes or CVD were observed. ApoA1, ApoB, and oxLDL levels may be promising markers of COVID-19.